Recent studies have reported that GPR109A can significantly inhibit the inflammatory response in different diseases such as Alzheimer’s Disease, mastitis, sepsis, obesity, diabetes, and colitis, following activation by its ligands (10). Here, HCAR2 is linked to diabetes mellitus.